Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20203969 | 0.92 | CYP1A2 (0.58) | CYP1A2SCN5ASCN1ASCN2ADYRK1A | |
| SCHEMBL26539441 | 0.88 | SCN5A (0.46) | CYP1A2SCN5ASCN1ASCN2ACACNA2D1 | |
| SCHEMBL26539329 | 0.82 | SCN5A (0.50) | CYP1A2SCN5ASCN1ASCN2ACACNA2D1 | |
| SCHEMBL26539447 | 0.82 | SCN5A (0.50) | CYP1A2SCN5ASCN1ASCN2ACACNA2D1 | |
| SCHEMBL26539353 | 0.81 | SCN5A (0.49) | CYP1A2SCN5ASCN1ASCN2AL3MBTL1 | |
| SCHEMBL26539455 | 0.81 | SCN5A (0.49) | CYP1A2SCN5ASCN1ASCN2AL3MBTL1 | |
| SCHEMBL26539463 | 0.81 | CYP1A2 (0.50) | CYP1A2SCN5ASCN1ASCN2ADYRK1A | |
| SCHEMBL20191087 | 0.78 | SCN5A (0.57) | CYP1A2SCN5ASCN1ASCN2AL3MBTL1 | |
| SCHEMBL20203983 | 0.78 | SCN5A (0.57) | CYP1A2SCN5ASCN1ASCN2AL3MBTL1 | |
| SCHEMBL26539438 | 0.78 | SCN5A (0.46) | CYP1A2SCN5ASCN1ASCN2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.